イドロン酸2スルファターゼ治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Iduronate 2 Sulfatase - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0833
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Iduronate 2 Sulfatase – Pipeline Review, H1 2020
Summary

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.

The latest report Iduronate 2 Sulfatase – Pipeline Review, H1 2020, outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Overview
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Companies Involved in Therapeutics Development
Bioasis Technologies Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Sangamo Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Drug Profiles
DNL-310 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-141 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-913 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xB-3008 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Dormant Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Discontinued Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) – Product Development Milestones
Featured News & Press Releases
Jan 29, 2020: REGENXBIO announces presentations at the 16th Annual WORLDSymposium 2020
Dec 18, 2019: REGENXBIO announces interim data from phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II)
Sep 09, 2019: CANbridge Pharmaceuticals’ Hunterase Granted Priority Review by the Chinese National Medical Products Administration
Jul 29, 2019: CANbridge Pharmaceuticals submits New Drug Application for Hunterase for the treatment of Hunter Syndrome in China
Jun 11, 2019: Denali Therapeutics receives orphan drug and rare pediatric disease designation for DNL310, and expands its portfolio of brain penetrant enzyme replacement programs
Apr 02, 2019: Sangamo provided an update on its in vivo genome editing program: SB-913
Feb 28, 2019: JCR completes patient enrollment in phase 2 clinical trial of JR-141 for Hunter Syndrome in Brazil
Feb 28, 2019: JCR receives EMA Orphan Designation for JR-141 in Hunter Syndrome
Feb 07, 2019: Sangamo announces interim results of phase 1/2 CHAMPIONS study showing preliminary evidence of in vivo genome editing in patients with MPS II treated with SB-913
Feb 01, 2019: Sangamo Therapeutics to host conference call to review interim results from phase 1/2 CHAMPIONS study for Mucopolysaccharidosis type II
Jan 04, 2019: Sangamo announces upcoming clinical data Presentation on SB-913 At WORLDSymposium 2019
Dec 28, 2018: JCR completed enrollment in phase 3 clinical trial of JR-141 in Japan for Hunter syndrome
Dec 21, 2018: Notice on the publication of the phase 1/2 clinical trial results for hunter syndrome in molecular therapy
Oct 19, 2018: JCR Pharmaceuticals: Notice of Orphan Drug Designation by the US Food Drug Administration for JR-141 for Hunter Syndrome
Sep 05, 2018: Sangamo Announces 16 influential fall week clinical results including reductions in glycosaminoglycans in phase 1/2 trial evaluating SB-913, a zinc finger nuclease genome editing treatment for MPS II (Hunter Syndrome)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Bioasis Technologies Inc, H1 2020
Pipeline by Denali Therapeutics Inc, H1 2020
Pipeline by Esteve Pharmaceuticals SA, H1 2020
Pipeline by GC Pharma, H1 2020
Pipeline by JCR Pharmaceuticals Co Ltd, H1 2020
Pipeline by RegenxBio Inc, H1 2020
Pipeline by Sangamo Therapeutics Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

【掲載企業】

Bioasis Technologies Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Sangamo Therapeutics Inc
Takeda Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[イドロン酸2スルファターゼ治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆